Entering text into the input field will update the search result below

Minerva Neurosciences shares surge on late-stage schizophrenia study data

  • Minerva Neurosciences (NASDAQ:NERV) shares surge over 35% during post-market trading after the company posted promising results from its open-label extension (OLE) of the late-stage trial of roluperidone for the treatment of negative symptoms (NS) of schizophrenia.
  • In the double-blind, placebo-controlled portion of the Phase

Recommended For You

About NERV Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
NERV--
Minerva Neurosciences, Inc.